Ipsen’s Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic…
Ipsen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde (irinotecan liposome injection) plus oxaliplatin,…
Read More...
Read More...
